Mechanism of Action
NMUR1 and NMUR2 Receptor Signaling
NMU activates NMUR1 (primarily Gq-coupled, peripheral) and NMUR2 (Gq and Gi-coupled, central), generating IP3/DAG and calcium release in target cells. In the hypothalamus, NMUR2 activation in the paraventricular nucleus reduces food intake and increases energy expenditure independently of leptin/" class="wiki-internal-link">leptin signaling. In the periphery, NMUR1 activation in the GI tract increases smooth muscle contraction and ion secretion.
Energy Homeostasis and Appetite
Central NMUR2 activation suppresses food intake acutely and chronically. NMU is released postprandially and acts in the hypothalamic energy balance circuits alongside CRF, urocortin, and leptin. NMU-deficient mice develop late-onset obesity and hyperphagia, establishing NMU as an endogenous anorexigenic signal. Unlike leptin, NMU's appetite effects persist in leptin-resistant states, supporting interest in NMU-based obesity therapies.
Research Summary
Obesity and Metabolic Regulation
AnimalICV NMU injections dose-dependently reduce food intake and body weight in both lean and obese mice. Chronic ICV NMU administration reduces fat mass without reducing lean mass, suggesting fat-selective energy mobilization. NMU also increases brown adipose tissue thermogenesis via NMUR2 in the hypothalamus.
Stress and HPA Axis
AnimalNMU activates the hypothalamic-pituitary-adrenal (HPA) axis by stimulating CRF release from the paraventricular nucleus and directly stimulating acth/" class="wiki-internal-link">ACTH release. Central NMU injection produces stress-like behavioral responses. The NMU system appears to be a physiological amplifier of acute stress responses.
Pain Sensitization
AnimalSpinal NMU enhances pain sensitivity (hyperalgesia) through NMUR2 activation in dorsal horn neurons, modulating glutamatergic pain transmission. This pro-nociceptive role makes NMUR2 antagonism a target for chronic pain, representing a non-opioid approach to pain management.
Calculate your Neuromedin U dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Appetite suppression | 1-10 nmol | Single ICV injection | Intracerebroventricular (animal) |
| GI motility research | 1-100 nmol/kg | Single dose | Subcutaneous or IV (animal) |
Central delivery (ICV) is required for hypothalamic appetite effects. Peripheral NMU has limited CNS penetration. Stable NMU analogs with CNS activity are under development.
Interactions
Safety Profile
Animal studies have not identified significant toxicity at effective doses. The HPA axis activation effect of NMU raises concerns for chronic stress responses with prolonged exposure. No human safety data exists. Central delivery requirements for current NMU formulations represent a significant clinical development challenge that is being addressed through stable peripherally active NMU analogs.
References
- [1]Minamino N, et al. Neuromedin U: a novel uterus stimulating and hypertensive peptide identified in porcine spinal cord. Biochem Biophys Res Commun. 1985.
- [2]Hanada R, et al. Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway. Nat Med. 2004;10(10):1067-1073.
- [3]Brighton PJ, et al. Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol Rev. 2004.